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ABSTRACT 
Objective: To compare the convulsive profile of three different Fluoroquinolones namely Ciprofloxacin, Levofloxacin and Ofloxacin using Maximal 
Electro Shock (MES) as an experimental seizure model.  
Methods: Wistar rats were divided into 8 groups with 6 animals each. Group I was administered Gum acacia 1 % solution (control), Group II with 
Standard drug, Sodium Valproate and Group III-VII received 25 mg/kg and 50 mg/kg of Ciprofloxacin, Levofloxacin and Ofloxacin each respectively. 
After 45 min of administration of drugs, animals were subjected to MES. 
Results: Ciprofloxacin prolonged various phases of MES, Ciprofloxacin 50 mg/kg group increased Tonic Hindlimb Extensor (THE) duration by 91% 
compared to the control group which was statistically significant. Levofloxacin group exhibited pro convulsive activity which was not significant. 
Ofloxacin 50 mg/kg group exhibited 80% reduction in the duration of tonic hind limb extensor phase and early recovery phase compared to control 
group (4.2±1.09 s and 169.33±5.3 s) respectively, proven statistically significant. Ofloxacin group exhibited anticonvulsant like activity.  
Conclusion: Fluoroquinolones are the popular class of antimicrobials used in a variety of infections. However, conflicting experimental evidence 
regarding central neurotoxicity especially seizures, complicate their use and required further investigation. Our results suggest that older 
generation Fluoroquinolones like Ciprofloxacin exhibits significant dose-dependent pro convulsive activity. Hence, their use must be judiciously 
restricted in patients with predisposing epileptogenic factors. Levofloxacin had no significant pro convulsant activity. Ofloxacin on higher dose 
appears to be protective exhibiting an anticonvulsant like activity. Hence, if need be, newer generation Fluoroquinolones should be preferred. 
Keywords: Fluoroquinolones, Ciprofloxacin, Levofloxacin, Ofloxacin, MES, Anticonvulsant. 
 
INTRODUCTION 
A seizure is the physical finding or changes in behavior that occur 
after an episode of abnormal electrical activity in the brain [1]. 
Seizures can occur due to many reasons ranging from abnormality in 
electrolyte levels to serious cerebral infections, injuries or tumors, 
systemic causes like fever, uremia, hypoglycemia, multi-organ 
failures, other cause like poisonings, drug withdrawals etc. Seizures 
are also a serious complication associated with certain drug use. It is 
estimated that 6.1% of new onset seizures are drug related [2]. It is 
essential for clinicians to understand drugs causing seizures in order 
to monitor and to treat the patient promptly. Even though seizures 
could be a feature of the underlying disease, convulsive episodes are 
also reported with the use of a number of antimicrobial agents used 
in therapy (fluoroquinolones, penicillins, monobactams, and 
carbapenems) [3]. 
Fluoroquinolones have recently gained much attention recently due 
to their adversities from different health-care perspectives. Their 
common adverse effects ranges from mild reactions like headache, 
nausea, vomiting, diarrhea, to severe ones like photosensitivity, 
visual disturbances, insomnia, hepatic and renal insufficiency, 
tendinopathy, prolongation of QT interval, neurotoxicity and 
neuropathy [4, 5]. Adverse event reporting for antibiotics found that 
12.2% of adverse reaction reports concerning fluoroquinolones 
involved the central nervous system (CNS) versus 3.6% for other 
antibiotics [6, 7]. CNS adverse effects include headache, dizziness, 
depression, seizures, hallucination, anxiety, insomnia, dizziness and 
encephalopathy are well established in preclinical studies and 
occurs in 1-7% of patients under the treatment with quinolones, 
complicating their clinical use [8]. Ascertaining the probable clinical 
course and likelihood for complications related to fluoroquinolone 
induced seizures can guide clinical decisions, foster cost-effective 
management, and optimize treatment. Hence, there is a need for 
continued surveillance of safety and tolerability data is essential. 
The present study was carried out with the aim to evaluate the same 
and to compare and rank various generations of fluoroquinolones in 
the order of their convulsant activity. The drugs studied were Cipro 
floxacin, Levofloxacin and Ofloxacin using maximal electroshock 
induced seizures (MES) in Wistar albino rats. 
MATERIALS AND METHODS 
Adult Wistar albino rats of either sex weighing between 200-250 g 
were used for this study. Rats were procured from the central 
animal house of A J Institute of Medical Sciences, Mangalore. The 
animals were housed in groups of 3 animals per polypropylene 
cages in temperature-regulated rooms with air cooling and 12 h 
light and dark cycle, and had free access to food and water ad 
libitum. They were allowed to acclimatize to the laboratory 
conditions for a period of one week. The study was approved by the 
Institutional Animal Ethics Committee, A J Institute of Medical 
Sciences, Mangalore and all the experiments were performed as per 
the Committee for the purpose of control and supervision on 
experiments on animals (CPCSEA) guidelines. The animals were 
subjected to experimentation between 0900-1600 h in noise-free 
atmosphere with ambient temperature 23-30 °C.  
Chemicals and drugs 
The drugs and chemicals used for the experiment were of analytical 
grade. All the drugs were suspended in vehicle 1% gum acacia 
solution. 
Methodology [9] 
Animals were divided into eight groups. For all the procedures, 6 
rats were randomly allocated to each of the groups which are given 
in table 1. Group I served as control and received gum acacia. Group 
II received the standard drug, (sodium valproate 100 mg/kg). 
Remaining groups received fluoroquinolones namely ciprofloxacin, 
levofloxacin and ofloxacin in two doses each (25 and 50 mg/kg 
orally) respectively for the acute study. 
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Table 1: Groups & dosages 
S. No. Groups Drugs* Dosage 
1) Control Gum Acasia 1 % solution 10 ml/kg 
2) Standard Sodium Valproate 100 mg/kg 
2) Test 1 Ciprofloxacin 25 mg/kg 
3) Test 2 Ciprofloxacin 50 mg/kg 
4) Test 3 Levofloxacin 25 mg/kg 
5) Test 4 Levofloxacin 50 mg/kg 
6) Test 5 Ofloxacin 25 mg/kg 
7) Test 6 Ofloxacin 50 mg/kg 
*All the drugs were suspended in vehicle-1% gum acacia solution and given once daily, orally 
 
Maximal Electroshock seizures (MES) 10 After 45 min of drug dosing, 
animals were subjected to Maximal electroshock seizure (MES) by an 
electrical stimulus of 50 mA (milliampere), for 0.2 s by using electro 
convulsiometer via ear clip electrodes. The duration in seconds of tonic 
flexion, tonic extension, clonic convulsion and post ictal depression were 
noted. The increase in the duration of the tonic extension was 
considered as the index of epileptic activity and vice versa. 
Statistical analysis 
The data were represented by mean±Standard error of mean (SEM). 
Statistical analysis was carried out using IBM SPSS version 22 
software. We used one-way ANOVA followed by posthoc Tukey test 
for analyzing the MES parameters between the groups. A p value less 
than 0.05 was considered statistically significant. 
RESULTS 
The results of the effect of Fluoroquinolones on Maximal Electroshock 
Seizures from our present study is summarized in table 2. 
Effect of Fluoroquinolones on onset of tonic hind limb extension 
(THE) in MES 
On application of electroshock, all animals went into different 
phases of convulsions. The duration of tonic extensor phase was 
4.2±1.09 s in the control group (table 2). Ciprofloxacin prolonged 
various phases of MES in a Dose-dependent pattern. Ciprofloxacin 
25 mg/kg and 50 mg/kg significantly increased onset time of tonic 
hind limb extensor phase at 5.96±0.46 and 5.3±0.03 s respectively 
from the control groups, effect on onset of THE by Levofloxacin and 
ofloxacin was neither dose dependent nor statistically significant. 
The effect on the onset of tonic hind limb extension was not 
statistically significant in any of the groups.  
Effect of Fluoroquinolones on duration of tonic hind limb 
extension (THE) in MES (fig. 1) 
The duration of THE in case of control group was 10.60±1.14 s, 
whereas ciprofloxacin 25 mg/kg and 50 mg/kg has dose-
dependently increased the duration of THE, 15.88±2.04 s and 
20.27±3.95 s respectively which was statistically significant for 
Ciprofloxacin 50 mg/kg group (p<0.01). The effect on the duration of 
THE produced by Levofloxacin was statistically insignificant 
(p>0.05). Ofloxacin reduced the duration of THE with respect to the 
Control group, in a dose-dependent manner 6.4±2.42 s and 
2.08±1.11 s. Ofloxacin 50 mg/kg reduced the duration of THE very 
significantly (p<0.001). 
Effect of Fluoroquinolones on recovery time in MES (table 2) 
Recovery time signifies the time taken by the animal to recover from 
the post ictal state after generalized tonic-clonic convulsions. 
Ciprofloxacin and levo floxacin at both the doses (25 and 50 mg/kg) 
tested did not alter the recovery time significantly. On the other 
hand, ofloxacin showed the dose-related reduction in recovery time. 
But, it was statistically significant only at the highest dose (50 
mg/kg) treated group (p<0.05). A similar reduction was seen in 
standard drug, sodium valproate treated group too. None of the 
animals died, during the observation period and 24 hours after the 
experiment. 
 
Table 2: Effect of fluoroquinolones on maximal electroshock seizures (MES) in rats n=6) 
S. No. Group mg/kg Onset of ‘THE’ (s) Duration of ‘THE’ (s) Duration of recovery (s) 
1 Control Gum Acasia 1% soln 4.2±1.09 10.60±1.14 169.33±5.3 
2 Standard Sod. valproate 10 mg/kg  3.2±0.54 2.01±0.54** 45.25±1.4** 
3 Ciprofloxacin 25 mg/kg 5.96±0.46 15.88±2.04 178±3.12 
4 Ciprofloxacin 50 mg/kg 5.3±0.03 20.27±3.95** 188.33±2.4 
5 Levofloxacin 25 mg/kg 4.7±1.2 8.05±2.69 140.60±6.15 
6 Levofloxacin 50 mg/kg 5.23±0.38 10.69±0.97 180.80±8.22 
7 Ofloxacin 25 mg/kg 4.98±1.56 6.44±2.42 153.80±s9.27 
8 Ofloxacin 50 mg/kg 3.91±1.2 2.08±1.11** 109.50±7.0* 
(Values expressed as mean±SEM). *=P<0.05, ** = p<0.01 compared with control group.) 
 
 
Values expressed as mean±SEM). *=P<0.05, ** = p<0.01 
compared with control group 
Fig. 1: Duration of tonic hindlimb extension in maximal 
electroshock seizures in albino rats 
DISCUSSION 
Fluoroquinolones are a popular class of antimicrobial agents 
prescribed in a variety of infections caused by gram negative, gram 
positive and atypical bacteria. They are mainly classified into four 
generations based on the year of their discovery. The antimicrobial 
activity of fluoroquinolones is due to the inhibition of bacterial DNA 
gyrase [4]. Fluoroquinolones are wonderful antibiotics, however, 
there is preclinical as well as clinical evidence demonstrating their 
neurotoxic potential. Neurological toxicity may manifest as mild 
reactions like headache, dizziness, insomnia, irritability to severe 
forms like convulsions, psychotic episodes or hallucinations even 
though they are rarely observed in day to day practice.  
However, there is black box warning for fluoroquinolones and they 
should be avoided in epileptics, and patients presenting with various 
central nervous system lesions to prevent neurologic complications [11]. 
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The mechanisms of neurotoxicity have been attributed to their 
interactions with different receptor complexes such as blockade of 
the GABA-A receptor complex within the central nervous system, 
leading to excitotoxic type effects and oxidative stress [12, 13]. 
In the present study, Ciprofloxacin produced a dose-dependent pro 
convulsive effect than the other fluoroquinolones studied and the 
results were similar to studies reported earlier [14]. The pro 
convulsants activity of fluoroquinolones has a correlation with the 
chemical structure. 
The R7 side chain substituent appears to have maximum influence 
on the degree of GABA binding inhibition; Larger the side chain 
substitution (R7) in the chemical structure of fluoroquinolones (fig. 
2), lower the binding affinity for GABA receptors [12]. The R7 side 
chain substituent, particularly unsubstituted piperazinyl, and 
pyrrolidinyl moieties appear to dictate affinity for the GABA 
receptor [15]. In agents with an unsubstituted piperazinyl ringlike 
ciprofloxacin, enoxacin, and norfloxacin,the R7 side chain 
substituent, demonstrate high-affinity binding to GABA-A and 
interfere with GABA binding to its receptor. [16] In our study, 
ofloxacin, which are having heavier side chains at R7 displayed 
anticonvulsant like activity. The GABA-A antagonistic property of 
ciprofloxacin was demonstrated previously using rat vagus nerve 
preparation which further substantiate our results of Ciprofloxacin 
having high pro convulsant activity [17]. 
Ofloxacin has higher CNS penetration but the lower affinity to GABA 
[18] as compared to other fluoroquinolones which could be the 
reason why it did show protective activity in the present study. 
Apart from GABA receptor binding theory, other reason attributed 
for such activity could also be due to by altered pharmacokinetics 
due to concurrent administration of other drugs [6]. Experimental 
data suggest that the chondro toxicity of fluoroquinolones could be 
due to their magnesium chelating property [19]. Similarly, in the 
central nervous system they might abolish Mg2+in the ion channels 
associated with activation of excitatory NMDA receptors which may 
prolong the duration of opening of the channels thus increasing the 
intracellular Ca2+concentrations and the excitability of the neurons 
[20]. This magnesium antagonistic property again might be 
contributive to the excitatory potency and neurotoxicity of 
fluoroquinolones [21]. 
From the available clinical literature, it is difficult to put 
fluoroquinolones in a relative order according to pro convulsive 
property. Therefore in this preclinical in vivo research we tried to 
compare the relative pro convulsive potential of these drugs so that 
the results obtained will help the clinicians to make better decisions 
on choosing the appropriate Fluoroquinolones in patients more 
prone for convulsive episodes. The same can be considered during 
drug designing & development of newer fluoroquinolone molecules 
with better efficacy and negligible neurotoxicity. 
 
   
Ciprofloxacin Levofloxacin Ofloxacin 
Fig. 2: Chemical structure of Fluoroquinolones 
 
CONCLUSION 
The results of the present study suggest that older generation 
Fluoroquinolones like Ciprofloxacin exhibits significant dose-
dependent pro convulsive activity.  
Hence, their use must be judiciously restricted in patients with 
predisposing epileptogenic factors. Levofloxacin had no significant 
anticonvulsant activity. Ofloxacin higher dose appears to be 
protective, having anticonvulsant like activity. Hence, if need be, 
newer generation Fluoroquinolones should be preferred. 
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